Poolbeg Pharma plc

We are attending EBD Group's BIO-Europe Autumn, in Stockholm on 4-6 November. BioEurope brings together global leaders, entrepreneurs & scientific researchers from the #biotech industry to share insights, forge collaborations and explore the latest trends shaping the future of #healthcare. Get in touch to meet us there! https://lnkd.in/dnuNZ2D #POLB #BIOEUROPE

Greetings from Barcelona 👋 Our CEO Jeremy Skillington, PhD attended last week's World Orphan Drug Congress Europe. This event is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. Jeremy enjoyed meeting with industry colleagues & potential partners to discuss Poolbeg Pharma plc's commitment to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. #POLB #OrphanDrugs #ScientificResearch #Barcelona

Our Chairman Cathal Friel has been shortlisted for the Business Person of the Year award 2024, in association with KPMG by Business & Finance Media Group. The awards will be presented on 5 December in Dublin. Good luck to all fellow short-listed finalists. #POLB #BandFAwards #BusinessPerson #Entrepeneur

Our last few posts have featured our Principal Scientist Liam Tremble. Liam Tremble is the lead on a number of Poolbeg Pharma’s early-stage discovery programs. Liam was one of Poolbeg’s first employees, having previously worked for the CRO, hVIVO, conducting human challenge trials. Liam has become the Project Lead for Influenza and RSV drug discovery AI programs, Scientific Advisor on drug candidate licencing opportunities, Project Lead on non-dilutive funding opportunities and grant writing and Scientific Lead on product repositioning and indication expansion. He has a particular interest in immunomodulatory therapies for the prophylaxis and treatment of infectious diseases. Identifying new opportunities to improve patient outcomes and bring new products to the clinic drives him in his day-to-day work at Poolbeg Pharma plc. Liam has a PhD in Translational Cancer Research from University College Cork, having previously being trained as an Immunologist at Trinity College Dublin (BSc and MSc) #POLB

GLP-1 receptor agonists are a hot topic for 2024 & we have shared a Q&A series with our Principal Scientist Liam Tremble to help digest this booming industry. 🤔 How do they work? ✅ Oral GLP-1R 🔬 Understanding the clinical use 💊 POLB's licensed encapsulation technology If you missed the series, catch up on the full interview here: https://lnkd.in/eN2Vy9xq #POLB #OralGLP1 #Diabetes #Obesity #ScientificRearch

A BBC News article highlights the NHS and University of Cambridge’s joined forces to create a “kinder” treatment for people with cancer.   The article highlights that ~30% of patients receiving CAR T cell treatment might need to spend time in the intensive care unit.   While the hope is for the lab to explore making therapies more effective and less toxic for patients, Poolbeg Pharma plc is developing a preventative therapy targeting cancer immunotherapy-induced CRS, which has the potential to positively impact patients & healthcare systems worldwide by enabling broader, safer delivery of these therapies to the cancer patients who need them.   Read the article here: https://lnkd.in/ep9buQJB   ✍️ Janine Machin

Snapshots 📷 taken by our CEO Jeremy Skillington, PhD at this weeks' Festival of Biologics in Basel, Switzerland. Jeremy presented 📣"Cytokine Release Syndrome, an Obstacle to Expanded Uptake of Cancer Immunotherapies: Clinical Development of an Oral Prophylactic" on Wednesday. Thank you to everyone who attended our session! 🙌 #POLB #FestivalofBiologics #Switzerland

Insightful Financial Times article around the significant developments being made in cancer immunotherapy. 🏥 The first paediatric patient to receive CAR T cell therapy has been cancer-free since 2012 but the therapy "induced a raging fever.. and she had to be put into a medically induced coma." 🔬 Remission rates for patients with some forms of blood cancers treated with CAR T-cell therapy can exceed 80 per cent. 🧬 c. 2.7k cell therapies are under development with an astonishing rate of innovation We hope that #POLB 001 can help to realise the full potential of CAR T-cell therapy to address this significant unmet need. https://lnkd.in/eAuuZDqk #CART #CellTherapy #Cancer #CancerTreatment #Cancers #POLB

Hear more about how our licensed encapsulation technology and why it is unique. 💊 Challenge of developing a reliable and effective drug 💪 Protection of peptides and delivering to the gut 👩🔬 Manufacturing process that can protect the protein #POLB #Technology #Healthcare #OralDrugs #ScientificResearch

A reminder that our CEO, Jeremy Skillington, PhD will be presenting in-person at the upcoming Festival of Biologics: 🎤 Title: Cytokine Release Syndrome, an Obstacle to Expanded Uptake of Cancer Immunotherapies: Clinical Development of an Oral Prophylactic 🩺 Session: Antibodies for Immunotherapy 📍 Location: Hall 1, Messe Basel, Basel, Switzerland 📅 Date/Time: 16 October 2024 at 17:30pm CEST 💼 Looking to connect? Jeremy will also be available for one-on-one meetings throughout the event. Get in touch to schedule a meeting ! Learn more: https://lnkd.in/gdZDuaR7 #POLB #FestivalofBiologics #Antibodies #Immunotherapy